Colleen Moretti

Findings from the phase 3 ARASENS trial indicate that darolutamide plus androgen-deprivation therapy and docetaxel should be considered a new standard of care for metastatic hormone-sensitive prostate cancer.

Yoga and conventional exercises also demonstrated long-term improvement in quality of life during treatment for non-metastatic breast cancer, according to results presented at the 2022 San Antonio Breast Cancer Symposium.

Updated results from the phase 3 TROPiCS-02 study demonstrated that the novel therapy improved overall survival, objective response rate, duration of response and overall quality of life compared with treatment of physician’s choice.

The radiotherapy schedules used in the ATLAS trial reflect recent evidence and guideline changes for its usage in patients with high-risk localized or locally advanced prostate cancer.

The results, however, showed that remaining on mobocertinib may be warranted for patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment.

The combination of ibrutinib plus the chemotherapy bendamustine and rituximab immunotherapy elicited the highest PFS rate ever reported for this patient population, according to an expert.

A Black patient with metastatic breast cancer explained that the results of the survey show that more work must be done by all stakeholders to increase the participation in clinical trials to accurately assess treatments in diversified populations.

New findings indicate that treatment with cabozantinib following failure of immunotherapy proved to be safe and feasible in metastatic renal cell carcinoma.

A safe and tolerable treatment option of transarterial chemoembolization combined with lenvatinib plus sintilimab was given to patients with hepatocellular carcinoma.

Patients with previously untreated chronic lymphocytic leukemia derived a better progression-free survival benefit from treatment with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab.

Patients with chronic lymphocytic leukemia who were treated with ibrutinib and venetoclax in the first line continued to demonstrate deep, durable responses with new data showing further benefit to continuous ibrutinib therapy after 2 years.

Yoga not only yields improvements in physical, mental, and sexual wellbeing, but it may also result in reduced inflammation and antitumor responses in men with prostate cancer.

Durable objective responses coupled with an acceptable safety profile were reported for sabizabulin in patients with metastatic castration-resistant prostate cancer at 2021 ESMO.

Treatment with axicabtagene ciloleucel resulted in improved survival and tumor responses in patients with relapsed/refractory follicular lymphoma versus other available therapies.

Compared with immediate prior therapy, selpercatinib resulted in a greater proportion of objective responses in patients with non–small cell lung cancer whose tumors harbor RET fusions.

A positive efficacy and safety profile persists with pralsentinib in RET fusion–positive non–small cell lung cancer, according to data presented at the 2021 ASCO Annual Meeting.

Specific resources needed for survivors of cancer to effectively cope during the first year after treatment were limited due to the COVID-19 pandemic, causing survivors to self-cope with known mechanisms.

Treatment care changed in the face of the COVID-19 pandemic as necessary virtual visits are proving to be more comfortable and safer for many Veteran patients and survivors of cancer.

First-line treatment with nivolumab plus cabozantinib demonstrated health-related quality of life benefits in patients with advanced renal cell carcinoma.

Data presented at the 2020 World Conference on Lung Cancer Singapore reported gains in survival at the population and patient levels for those with SCLC treated with immunotherapy.

Similar results with nivolumab and a matched placebo are reported with preliminary health-related quality-of-life data from the CheckMate 577 trial.

Women who survive breast cancer may have more difficulty in becoming pregnant when compared to the general population, and have a risk of preterm labor, but most deliver healthy babies and experience no detrimental effects on their long-term survival.